Understanding whats normal helps set expectations and keeps you prepared rather than surprised
In a normally functioning body, GLP-1 gets released after eating
Mornigo R, Vidal J, Lacy AM, Delgado S, Casamitjana R, Gomis R
Even clinicians who are not as familiar with these medications will ask me, 'I have a patient on Mounjaro who's not losing weight can we switch to Zepbound? without realizing its exactly the same drug. To complicate matters, pharmaceutical companies are quickly working on new drugs including triple agonists that target GLP-1, GIP and glucagon receptors as well as oral versions of each drug
October 4, 2024: Lawsuits Against Eli Lilly Escalate as Trulicity Side Effect Concerns Grow The number of lawsuits targeting GLP-1 drug manufacturers, including Eli Lilly, the maker of Trulicity, saw a 20% increase between August and September
Figures above summarize published clinical findings on the retatrutide molecule and are provided as scientific reference for laboratory research only
.png)
